Literature DB >> 18055782

Long-term suppression of neurodegeneration in chronic experimental optic neuritis: antioxidant gene therapy.

Xiaoping Qi1, Liang Sun, Alfred S Lewin, William W Hauswirth, John Guy.   

Abstract

PURPOSE: To test in mice with experimental autoimmune encephalomyelitis (EAE) a strategy designed to treat patients at risk for axonal degeneration and persistent visual loss from optic neuritis and multiple sclerosis.
METHODS: The authors cloned the human extracellular superoxide dismutase (ECSOD) or catalase (CAT) gene into recombinant adenoassociated virus (AAV). Transgene expression was evaluated by immunochemistry of infected RGC-5 cells and after intravitreal injection of AAV-ECSOD or AAV-CAT, or both, into the right eyes of DBA/1J mice. Control cells and left eyes were inoculated with AAV-GFP. Animals were sensitized for EAE, followed by serial contrast-enhanced MRI for 6 months, and then were euthanatized. The effects of ECSOD and CAT modulation on the EAE optic nerve were gauged by computerized analysis of optic nerve volume, myelin fiber area, axonal cell loss, and retinal ganglion cell (RGC) loss.
RESULTS: Western blot analysis of infected RGC-5 cells revealed that expression of ECSOD increased 15-fold and that of CAT increased 3.5-fold. One month after intraocular injections, transgene expression increased 4-fold for AAV-ECSOD and 3.3-fold for AAV-CAT. Six months after intraocular injections and EAE sensitization, combination therapy with ECSOD and catalase decreased RGC loss by 29%, optic nerve demyelination by 36%, axonal loss by 44%, and cellular infiltration by 34% compared with the contralateral control eyes inoculated with AAV-GFP. Compared with the normal optic nerve, it limited RGC loss to 9%.
CONCLUSIONS: Viral-mediated delivery of antioxidant genes provides long-lasting suppression against neuronal and axonal loss associated with permanent visual disability in patients with optic neuritis and multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055782     DOI: 10.1167/iovs.07-0254

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  24 in total

1.  Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.

Authors:  Grazyna Adamus; Lori Brown; Shayne Andrew; Roberto Meza-Romero; Gregory G Burrows; Arthur A Vandenbark
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-25       Impact factor: 4.799

Review 2.  The neuro-ophthalmology of mitochondrial disease.

Authors:  J Alexander Fraser; Valérie Biousse; Nancy J Newman
Journal:  Surv Ophthalmol       Date:  2010-05-14       Impact factor: 6.048

3.  Variations in mitochondrial DNA copy numbers in MS brains.

Authors:  Andrei Blokhin; Tamara Vyshkina; Samuel Komoly; Bernadette Kalman
Journal:  J Mol Neurosci       Date:  2008-06-20       Impact factor: 3.444

4.  Retinal gene therapy using adeno-associated viral vectors: multiple applications for a small virus.

Authors:  William W Hauswirth
Journal:  Hum Gene Ther       Date:  2014-08       Impact factor: 5.695

5.  Inflammatory cytokine induced regulation of superoxide dismutase 3 expression by human mesenchymal stem cells.

Authors:  Kevin Kemp; Elizabeth Gray; Elizabeth Mallam; Neil Scolding; Alastair Wilkins
Journal:  Stem Cell Rev Rep       Date:  2010-12       Impact factor: 5.739

Review 6.  Review: Mitochondria and disease progression in multiple sclerosis.

Authors:  D Mahad; H Lassmann; D Turnbull
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12       Impact factor: 8.090

7.  Increased expression of catalase and superoxide dismutase 2 reduces cone cell death in retinitis pigmentosa.

Authors:  Shinichi Usui; Keiichi Komeima; Sun Young Lee; Young-Joon Jo; Shinji Ueno; Brian S Rogers; Zhihao Wu; Jikui Shen; Lili Lu; Brian C Oveson; Peter S Rabinovitch; Peter A Campochiaro
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

8.  Analysis of the pathogenesis of experimental autoimmune optic neuritis.

Authors:  Takeshi Kezuka; Yoshihiko Usui; Hiroshi Goto
Journal:  J Biomed Biotechnol       Date:  2010-10-25

Review 9.  Gene therapy targeting glaucoma: where are we?

Authors:  Xuyang Liu; Carol A Rasmussen; B'ann T Gabelt; Curtis R Brandt; Paul L Kaufman
Journal:  Surv Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 6.048

10.  Benzothiazole aniline tetra(ethylene glycol) and 3-amino-1,2,4-triazole inhibit neuroprotection against amyloid peptides by catalase overexpression in vitro.

Authors:  Amrutha Chilumuri; Mark Odell; Nathaniel G N Milton
Journal:  ACS Chem Neurosci       Date:  2013-09-09       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.